Last updated on June 2019

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Brief description of study

Open label, single arm, multicenter phase II trial.

Detailed Study Description

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group.

PREVENE (PREemptive VENEtoclax) trial.

Clinical Study Identifier: NCT03766763

Find a site near you

Start Over


Caen, France
  Connect »